FDA Approves Moderna's RSV Vaccine for Adults Under 60 Amid Industry Uncertainty
TL;DR Summary
The FDA has expanded Moderna's RSV vaccine approval to include adults under 60 at increased risk, pending CDC advisory committee approval, marking a significant step in protecting more vulnerable populations from severe RSV illness.
- FDA expands approval of Moderna's RSV vaccine to some adults under age 60 ABC News
- Moderna falls on doubts over new CDC panel's backing of RSV vaccine Reuters
- FDA approves expanded use of Moderna’s RSV shot, but uncertainty remains The Hill
- FDA clears Moderna’s RSV vaccine for use in people aged 18 to 59 statnews.com
- Moderna Wins Expanded Label for mRNA RSV Shot as New ACIP Members Question mRNA Technology BioSpace
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 3 min read
Condensed
93%
476 → 34 words
Want the full story? Read the original article
Read on ABC News